At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Closed Christmas Day 12-24 12:08:29
35.800
+0.750
+2.14%
High36.150
Low34.400
Vol4.63M
Open35.050
D1 Closing35.050
Amplitude4.99%
Mkt Cap58.64B
Tradable Cap58.64B
Total Shares1.64B
T/O164.70M
T/O Rate0.28%
Tradable Shares1.64B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Innovent Biologics' Lung Cancer Drug Hets NDA Approval from China's NMPA
Innovent and HUTCHMED Jointly Announce Nmpa Conditional Approval for Tyvyt® (Sintilimab Injection) in Combination With Elunate® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
HUTCHMED and Innovent Jointly Announce Nmpa Conditional Approval for Elunate® (Fruquintinib) in Combination With Tyvyt® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.